Nisa Investment Advisors LLC Acquires 1,358 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Nisa Investment Advisors LLC grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 32.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,495 shares of the biopharmaceutical company’s stock after purchasing an additional 1,358 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $315,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Whittier Trust Co. purchased a new position in Halozyme Therapeutics in the first quarter worth $27,000. GAMMA Investing LLC increased its stake in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $49,000. Finally, Toth Financial Advisory Corp purchased a new stake in shares of Halozyme Therapeutics in the third quarter worth about $57,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.72, for a total value of $557,200.00. Following the sale, the director now owns 89,755 shares in the company, valued at approximately $5,001,148.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Matthew L. Posard sold 10,000 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $55.72, for a total value of $557,200.00. Following the sale, the director now directly owns 89,755 shares of the company’s stock, valued at approximately $5,001,148.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the transaction, the director now owns 69,874 shares of the company’s stock, valued at $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock valued at $5,169,834 in the last three months. Company insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Trading Up 3.3 %

NASDAQ HALO opened at $60.63 on Thursday. The firm has a market capitalization of $7.71 billion, a PE ratio of 20.08, a P/E/G ratio of 0.53 and a beta of 1.29. The stock’s 50 day moving average is $56.75 and its 200 day moving average is $52.48. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The firm had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.68 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on HALO shares. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, November 1st. TD Cowen boosted their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Piper Sandler upped their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.